Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."
Pfizer will sell two Novartis drugs in the UK.
Roche has beat out rumored competitors GlaxoSmithKline and Sanofi in a run-off to acquire California biotech InterMune.
The FDA has approved Arnuity Ellipta for asthma.
The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
It could also eat into Merck's Pneumovax sales.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.
AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
US sales fell 10%, and corruption allegations in China ate into emerging-market sales.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.
The FDA approved the Breo/Ellipta combo, but analysts are wary about its potential to go beyond the COPD indication in the US.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.